CCP-07

CCP-07 is a reformulated, extended‑release cough/cold product being developed by Vernalis in collaboration with Tris Pharma using Tris’ oral sustained‑release formulation technology for the US prescription cough and cold market.[9][10] It is one of multiple code‑named products in Vernalis’ cough/cold pipeline and has completed a pivotal multiple‑dose comparative bioavailability study intended to support a New Drug Application, although the FDA subsequently issued a Complete Response Letter on the NDA.[2][5][7][11] Publicly available information focuses on its development and bioavailability profile rather than disclosing the exact active ingredient(s), mechanism of action, or detailed clinical indication beyond its positioning as a prescription cough/cold therapy.[2][5][9][10]